Pharmaceutical Industry Research by Datamonitor
Posted by Deal Pro Team on Tue, Jan 19, 2010 @ 04:16 PM
Pharmaceutical Company Outlook to 2014
Datamonitor recently published their pharmaceutical company outlook to 2014 market research report. This appears to be a popular topic with the current healthcare debate going on right now in the U.S. With Datamonitor being one of the leading market research vendors, this report is sure to have solid pharmaceutical industry analysis and be useful in developing a strategic marketing plan.
We have provided some information below for your review including their introduction, scope of the report, market analysis highlights and their keys reasons to purchase the report.
Introduction:
PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.
Scope of research:
- Analysis of the sales outlook for the PharmaVitae universe of leading prescription pharma companies to 2014
- Assessment of the impact of future launches and patent expiries on sales growth compared to historical trends
- Segmentation of the market by therapy area and molecule type to assess high- and low-growth sectors of the industry
- Assessment of the impact of cost-cutting on operating profit growth in an environment of low and sometimes negative sales growth
Research highlights:
The increasing assault of generics on leading pharma players' staple diet of small molecule products will prompt a shake-up of the industry. Companies' success will be heavily linked to their exposure to this generic threat, with biologics and niche players enjoying the greatest insulation and therefore often the highest growth.
Many companies not in these hot sectors of the industry will be compelled to pursue cost-cutting to maintain previous levels of operating profit growth and some may resort to M&A activity to bolster sales performance and/or strategically realign themselves.
However, recourse to M&A should not be surprising when looked at in the historical context, as this has already acted as the PharmaVitae universe's primary growth driver in the period between 2002 and 2008, accounting for a greater proportion of growth than internal R&D operations.
Key reasons to purchase:
- Gain a true understanding of the threats facing the pharmaceutical industry's sales performance and which sectors will be most heavily impacted
- Assess the effectiveness of cost-cutting programs on operating profit performance in a period of low sales growth
- Evaluate the impact of M&A on companies' historical performance and see how low top-line sales growth could prompt a further wave of consolidation
Get the table of contents and sample pages for this pharmaceutical industry analysis. Also, let us know if you are looking for other new market research. We can help!